Latest News and Press Releases

BOSTON, Oct. 28, 2025 (GLOBE NEWSWIRE) -- NodThera, a clinical-stage biotech pioneering a paradigm shift in the treatment of chronic inflammatory diseases through NLRP3 inhibition, today announced...

NT-0796 is an oral, brain-penetrant NLRP3 inhibitor that selectively regulates chronic inflammation, a key driver of cardiometabolic diseasesExpects to complete the ongoing NT-0796 monotherapy trial...

NodThera Demonstrates Reversal of Neuroinflammation and Inflammation in Parkinson’s Disease with Oral NLRP3 Inhibitor Phase 1b/2a study results published in Movement Disorders journalOral,...

NodThera Announces Appointment of Dr. Jyothis George as Chief Medical Officer Former Amgen, Novo Nordisk and Boehringer Ingelheim senior leader joins NodThera Leadership TeamWill spearhead clinical...

NodThera Announces Appointment of Elisabeth Björk as Board Member Former SVP at AstraZeneca R&D brings deep expertise in obesity and cardiometabolic research, portfolio strategy development and...

NodThera Charts Obesity Future with First Patients Dosed in Phase 2 RESOLVE-1 Trial of Oral NLRP3 Inflammasome Inhibitor NT-0796 Pioneering small-molecule program, NT-0796, targets chronic...

Data published in Obesity journal show enhanced weight loss effect of NT-0796 when combined with semaglutide in preclinical obesity modelObese state completely reversed with 30% weight loss and...

NodThera Named a ‘Fierce 15’ Company by Fierce Biotech Philadelphia, PA, August 5, 2024 - NodThera, a leading clinical-stage biotech delivering a paradigm shift in the treatment of chronic...

NodThera Announces Appointment of Greg Chow as Chief Financial and Business Officer Greg brings over 25 years of public and private company leadership experience Philadelphia, PA, August 1, 2024 -...

NodThera Ltd (“NodThera” or the “Company”) NodThera’s NLRP3 Inhibitor NT-0796 Meets Primary Endpoint of Inflammation Reversal in Phase Ib/IIa Trial in Obese Subjects with Cardiovascular Risk ...